MBA in Biotechnology
23-24 years old
10 Months. Full Time
None to 2 years
94% of the students within the year
> 15 Nationalities
The objective of the program is to acquire a deep understanding in key aspects of processes involved in the set-up of biotechnology-based companies, fundraising private equity to develop the drug candidate, and the relationships between global departments of the pharmaceutical industry in order to develop later stages of clinical trials.
The main roles and companies related with these areas of knowledge’s are those such as, investment analyst, innovation science liaison, project leader, business development, financial consultant among other corporate positions at biotechnology-based companies or the pharmaceutical industry and other companies related to healthcare.
The main areas of work and topics are related with corporate management, entrepreneurship and innovation, financial valuations in biotech markets, venture funding and private equity and international business development in the life sciences sector.
The masters and postgraduate courses give the students applied knowledge about the Biotechnology sector beyond the laboratory, opening a new wide range of professional development and career opportunities
Esther Riambau - Life Science Director at UPF Ventures
We motivate entrepreneurship and innovation in Life Sciences. The students will not only acquire theoretical knowledge throughout the course, but also become an active part of the sector from the first day
William Hariri – Vice President at Locust Walk
The master's programs cover a growing unsatisfied necessity for scientific profiles that want to orient the professional career towards management, business and investment in applied research
Mireia Angulo - Senior Investment Analyst at Caixa Capital Risk
The Institute has a strong international attitude. That is why we encourage our students to take part in events related with the sector in order to build up their network from the very start of their career
Pablo Viguera - Medical Lead/Director Southern Cluster Kyowa Kirin International plc
The greatest thing is that all the Alumni are now part of the Biotech and Pharma sector, each of us growing in our own way and still doing science.
Beatriz Volckaert - Impact Investment Analyst at Ship2B & BBI Alumni